MyoKardia, Inc (acquired by BMS)

1000 Sierra Point Parkway
Brisbane, CA 94005
United States

Tel: 650-741-0900


NextGen Class of 2015
Show jobs for this employer

About MyoKardia, Inc (acquired by BMS)

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. MyoKardia is a clinical-stage bio pharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the bio mechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224. Founded in September 2012 MyoKardia is headquartered in Brisbane, CA.


MyoKardia Life

MyoKardia Life 2

MyoKardia Office 4MyoKardia Office 2MyoKardia Office 1

126 articles with MyoKardia, Inc (acquired by BMS)